Related Experiment Video

Updated: May 27, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Editorial: bugs and drugs: insights into the pathogenesis of inflammatory bowel disease

Geoffrey C Nguyen

    The American Journal of Gastroenterology
    |December 6, 2011
    PubMed

    Insights

    Antibiotic use may increase the risk of developing inflammatory bowel disease (IBD). A Canadian study found a link between antibiotic exposure and new-onset IBD, supporting the gut microbiome

    Area of Science:

    • Microbiome research
    • Gastroenterology
    • Epidemiology

    Background:

    • The gut microbiome plays a crucial role in maintaining intestinal homeostasis.
    • Dysbiosis, an imbalance in gut microbial communities, is implicated in various diseases.
    • Inflammatory Bowel Disease (IBD) encompasses chronic inflammatory conditions of the gut.

    Discussion:

    • A Canadian population-based study investigated the association between antibiotic use and new-onset IBD.
    • Findings suggest a correlation between antibiotic exposure in the 2-5 years prior to diagnosis and IBD development.
    • While not proving causation, this supports the dysbiosis hypothesis in IBD pathogenesis.

    Key Insights:

    • Antibiotic use is associated with an increased risk of developing IBD.
    • The gut microbiome's role in IBD pathogenesis is further supported by these findings.
    • Judicious antibiotic prescribing is emphasized to mitigate potential risks.

    Outlook:

    • Further research is needed to elucidate the causal mechanisms linking antibiotics, dysbiosis, and IBD.
    • Investigating specific antibiotic classes and their impact on the microbiome is warranted.
    • Longitudinal studies can provide deeper insights into the temporal relationship between antibiotic use and IBD onset.

    More Related Videos

    Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells06:57

    Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

    Published on: September 18, 2016

    Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach08:24

    Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

    Published on: May 2, 2018

    Related Concept Videos

    Inflammatory Bowel Disease III: Crohn's Disease01:25

    Inflammatory Bowel Disease III: Crohn's Disease

    Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
    Inflammatory Bowel Disease II: Ulcerative Colitis01:20

    Inflammatory Bowel Disease II: Ulcerative Colitis

    Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
    Inflammatory Bowel Disease I: Ulcerative Colitis01:27

    Inflammatory Bowel Disease I: Ulcerative Colitis

    Introduction
    Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
    Risk Factors
    The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
    Inflammatory Bowel Disease I: Introduction01:26

    Inflammatory Bowel Disease I: Introduction

    Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
    Inflammatory Bowel Disease II: Crohn's Disease01:30

    Inflammatory Bowel Disease II: Crohn's Disease

    Introduction
    Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
    Crohn's disease
    Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.